Lantern Pharma Inc.
LTRN | NASDAQ
$1.45
-$0.05 (-3.33%)
Sep 22, 2026, 11:56 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 174.84K | n/a | n/a | n/a |
Gross Profit | n/a | n/a | -174.84K | n/a | n/a | n/a |
Operating Income | -17.98M | -22.22M | -17.88M | -14.43B | -12.59M | -5.91M |
Interest Income | 437.93K | 742.36K | 765.39K | 204.36M | 67.93K | n/a |
Pretax Income | -17.12M | -20.78M | -15.96M | -14.26B | -12.36M | -5.91M |
Net Income | -17.12M | -20.78M | -15.96M | -14.26B | -12.36M | -5.91M |
Selling & General & Admin | 6.46M | 6.09M | 5.98M | 5.83B | 5.02M | 3.66M |
Research & Development | 11.51M | 16.13M | 11.89M | 8.6B | 7.57M | 2.24M |
Other Expenses | n/a | n/a | -174.84K | n/a | n/a | 0 |
Operating Expenses | 17.98M | 22.22M | 17.7M | 14.43B | 12.59M | 5.91M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 17.98M | 22.22M | 17.88M | 14.43B | 12.59M | 5.91M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 10.9M | 10.76M | 10.84M | 10.85M | 10.9M | 6.22M |
Shares Outstanding (Diluted) | 10.9M | 10.76M | 10.84M | 10.85M | 10.9M | 6.22M |
EPS (Basic) | -1.57 | -1.93K | -1.47 | -1.31 | -1.13 | -0.95 |
EPS (Diluted) | -1.57 | -1.93K | -1.47 | -1.31 | -1.13 | -0.95 |
EBITDA | -17.1M | -20.76M | -15.79M | -14.26B | -12.36M | -5.9M |
EBIT | -17.12M | -20.78M | -15.96M | -14.26B | -12.36M | -5.91M |
Depreciation & Amortization | 17.28K | 17.28K | 174.84K | n/a | 6.76K | 3.39K |
Add to Watchlist
Select watchlists to add or remove LTRN